In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model
- 595 Downloads
Preclinical in vivo analyses of treatment responses are an important prerequisite to evaluate new therapeutics. Molecular in vivo imaging in the far red (FR)/near infra red (NIR) is a promising method, as it enables measurements at different time points in individual animals, thereby reducing the number of animals required, while increasing statistical significance. Here, we show the establishment of a method to monitor response to treatment using fluorescent cells, expressing the epidermal growth factor receptor (EGFR), a target already used in therapy.
We transfected A-431 tumour cells with the far red–emitting protein Katushka (Kat2), resulting in strong fluorescence allowing for the monitoring of tumour growth when implanted in BALB/c nu/nu mice with a CRi Maestro in vivo imager. We targeted A-431 cells with a previously reported immunotoxin (IT), consisting of the anti-EGFR antibody single-chain variable fragment (scFv) 425, fused to Pseudomonas aeruginosa Exotoxin A’ (ETA’). In addition, EGFR expression was verified using the 425(scFv) conjugated to a NIR dye BG-747 through a SNAP-tag linker.
The results show the feasibility to evaluate response to treatment in vivo by FR imaging, while at the same location detecting EGFR expression. Treatment with 425(scFv)-ETA’ resulted in decelerated tumour growth, while not affecting the overall health of the animals. This is in contrast to treatment with Doxorubicin, which, although decreasing the tumour size, resulted in poor health.
We developed a novel method to non-invasively determine treatment responses by in vivo imaging of multiple parameters which showed the efficacy of 425(scFv)-ETA’.
KeywordsFluorescence imaging scFv immunotoxin Katushka EGF receptor Immunotherapy Treatment response
We thank Dirk Scheffler, Reinhard Rosinke and Peggy Jirak for excellent technical assistance. This publication is based upon work that was in part financed by the Bundesministerium für Bildung und Forschung (0315254A/B). The responsibility for the content of this publication lies with the author.
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Tolmachev V, Rosik D, Wållberg H, Sjöberg A, Sandström M, Hansson M et al (2010) Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imag 37:613–622CrossRefGoogle Scholar
- 10.Shao W, Zhao S, Liu Z, Zhang J, Ma S, Sato JD et al (2006) Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun 349:816–824PubMedCrossRefGoogle Scholar
- 19.Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, et al. (2001) Human angiogenin fused to human CD30 Ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 61:8737–8742Google Scholar
- 35.Kapp U, Wolf J, Von Kalle C, Tawadros S, Röttgen A, Engert A et al (1992) Preliminary report: growth of Hodgkin’s lymphoma derived cells in immune compromised mice. Ann Oncol 3:S21–S23Google Scholar